AHA: Mixed Results with Dapagliflozin in T2D Patients

(MedPage Today) -- SGLT2 inhibitor didn ' t change MACE rate, but did result in other positive CV outcomes
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news